1. INTRODUCTION {#sec1-1}
===============

Atrial fibrillation represents the most common cardiac arrhythmia in clinical practice. Patients with AF have significantly poorer quality of life than healthy controls. Despite good progress in the management of patients with AF, this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity all over the world. In 2010, the estimated numbers of men and women with AF worldwide were 20.9 million and 12.6 million, respectively. By year 2030, 14-17 million AF patients are anticipated in the European Union, with 120,000 - 215,000 newly diagnosed patients annually.

2. REASEARCH OBJECTIVES {#sec1-2}
=======================

The first objective of our study is to determine the cardiac and cerebrovascular events (myocardial infarction, heart failure, stroke, sudden cardiac death) and their cumulative incidence during median follow up period 9.7 ± 1.8 years (September 2006 - September, 2016).

3. PATIENTS AND METHODS {#sec1-3}
=======================

This study includes 2352 ambulant and hospitalized patients with atrial fibrillation (AF) who were enrolled during median 9.7 ± 1.8 follow up period (September 2006 until September, 2016). A complete medical history was taken and all patients underwent clinical evaluation which includes thorough assessment for concomitant conditions, establishing the AF pattern, estimation of stroke, myocardial infarction, heart failure and sudden death risk. The AF was documented by 12-lead ECG or ambulatory ECG Holter recording. All patients were subjected to echocardiography to assess left atrial diameter and volume. In this study the following types of AF were included: newly diagnosed, paroxysmal, persistent and permanent AF. During the follow up period, cardiac and cerebrovascular events were evaluated (myocardial infarction, heart failure, stroke, sudden death) and their cumulative incidence.

4. RESULTS {#sec1-4}
==========

During the follow up period, we analyzed and follow up 2352 patients with ECG documented different type of atrial fibrillation in order to evaluate the cumulative incidence of sudden death, stroke, myocardial infarction and heart failure. The demographic data, risk factors, clinical and comorbidity characteristics for all patients are shown on [Table 1](#T1){ref-type="table"}. The cumulative incidence of sudden death, stroke, myocardial infarction and heart failure is shown on [Figure 1](#F1){ref-type="fig"}.
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In our study among 2352 patients, AF was reported to be first detected in 352, paroxysmal in 194, persistent in 728, and permanent in 1078 patients. Concomitant diseases were present in 84% of all patients. Oral anticoagulation with VKA~s~ was prescribed in 35% and NOAC~s~ in 44% of patients, respectively. A rhythm control strategy was applied in 63% of currently symptomatic patients and in 47% of patients who never experienced symptoms according to the ESC guidelines.

In our study the age-adjusted incidence and prevalence of AF are slightly lower in women. The study shows that the risk of death is higher in females than that in males with AF, the risk of stroke is higher also in women with AF. The risk of myocardial infarction in our study was higher in men, the study shows that the risk of heart failure was almost same in both gender.

During median follow up period 9.7 ± 1.8 years, the cumulative incidence for sudden cardiac death was 1.71%, for stroke 2.56%, for myocardial infarction 1.20 and for heart failure was 5.73%. Our study shows that the majority of patients with atrial fibrillation have mild to moderate enlargement of left atrium, more than half of patients have mildly-moderately reduced LV EF.

5. DISCUSSION {#sec1-5}
=============

Atrial fibrillation is the most common arrhythmia in the general population, with a prevalence of 1.5-2%, which increases with age. In addition, it occurs more frequently in males, with a male to female ratio of 1.2:1. In 2010, the estimated numbers of men and women with AF worldwide were 20.9 million and 12.6 million, respectively, with higher incidence and prevalence rates in developed countries. One in four middle-aged adults in Europe and the US will develop AF. By 2030, 14-17 million AF patients are anticipated in the European Union, with 120 000 - 215 000 newly diagnosed patients per year. Given that AF is associated with significant morbidity and mortality, this increasing number of individuals with AF will have major public health implications ([@ref1]-[@ref7]).

In our study, the mean age of the patients was 68 ± 13 years, the males represent 52% of patients with AF. The published studies also have reported a predominance of males (generally around 60%), the mean age of the patients in most reports is between 65 and 70 years, which is comparable to the mean age of our population ([@ref8], [@ref9]).

In our study, family history of CAD was present in 31% of patients with AF, \[HR 1.543 (CI 1.359 - 1.746)\], also CAD was found in 39% of patients \[HR 0.916 (CI 0.763 - 1.069)\], which is in consistent with the results of published studies. Violi F et al. In their investigation they searched MEDLINE via PubMed and Cochrane database between 1965 and 2015. All observational clinical studies and interventional trials reporting 1 year incidence of MI in AF were included. The main conclusion was that AF patients had a significant residual risk of MI despite anticoagulant treatment ([@ref10]).

Echocardiography provides vital information about cardiac chambers and function, complications, and prognosis in patients with AF. This information may be helpful in determining the conditions associated with AF, the risk for recurrent AF following cardioversion, and the hemodynamic benefit of maintaining sinus rhythm, also identification of patients at increased risk for thromboembolic complications of AF before cardioversion and in patients with chronic AF ([@ref11]-[@ref15]).

In the reviewed literature, the prescription of oral anticoagulation on hospital discharge was also lower in patients with paroxysmal vs. permanent AF (51 vs. 80%, 55 vs. 74%, 78 vs. 91%). In a Swiss registry of outpatients with AF seen by cardiologists, prescription of anticoagulants reached 88% in patients with a CHADS2 score ≥ 1. However, 57% of the patients with a score of zero also received anticoagulants ([@ref16]-[@ref19]).

During median follow up period 9.7 ± 1.8 years, the cumulative incidence for sudden cardiac death was 1.71%, for stroke 2.56%, for myocardial infarction 1.20 and for heart failure was 5.73%. The cumulative incidences of stroke, myocardial infarction, heart failure and sudden cardiac deathare similar to those in published studies and meta-analysis. The published studies shows the following cumulative incidence for stroke 5-7.5%, MI 0.4--2.5%, heart failure 6-35% ([@ref1]-[@ref4], [@ref7], [@ref8]).

Krijthe BP et al. had estimated that from 2010 to 2060, the number of adults 55 years and over with AF in the European Union will more than double. As AF is associated with significant morbidities and mortality, this increasing number of individuals with AF may have major public health implications ([@ref20]). In other systematic review by Wolowacz S.E. et al. for the economic burden of AF, hospitalizations consistently represented the major cost driver. In the USA, AF hospitalizations alone cost \$6.65 billion in 2005. Costs and hospitalizations attributable to AF have increased markedly over recent decades and are expected to increase in future due to ageing populations ([@ref21]).

6. CONCLUSION {#sec1-6}
=============

Despite good progress in the management of patients with atrial fibrillation (AF), this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. AF is associated with a 4-fold increase in the risk of stroke, 3-fold increase in the risk of heart failure, and 1.5-1.9 increased risk of death. Death. AF is known to have a significant impact on healthcare costs, with the major cost drivers being hospitalizations, stroke, and loss of productivity. Atrial fibrillation should be considered as a manifestation of hypertensive heart disease. Effective treatment of patients with atrial fibrillation includes not only rate control, rhythm control, and prevention of stroke, but also management of cardiovascular risk factors and concomitant diseases.
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